Resolute® and xience V® polymer‐based drug‐eluting stents compared in an atherosclerotic rabbit double injury model

• DOI: 10.1002/ccd.24595
• Publication Date: 2012-08-06T10:35:26Z
• Authors: Christophe J. Van...; Vicky Y. Hoymans; Hidde Bult; Erik Fransen; Steven Haine; Johan M. Bosmans; Jean‐Pierre Timme...; Christiaan J. Vrints
• Keywords: Atheroma

To evaluate differences in strut coverage, inflammation and endothelialization between two second-generation polymer-based drug-eluting stents (DES) an atherosclerotic rabbit double-injury iliac artery model at 28 days follow-up.Rabbits with induced atheroma received bilateral stents: everolimus-eluting stent (Xience V EES; Abbott Vascular), zotarolimus-eluting (Resolute ZES; Medtronic CardioVascular), or bare-metal (BMS; MultiLink Vision; Vascular). After days, total neointimal coverage examined by scanning electron microscopy was >98% for all three types. Neointimal thickness above struts decreased 50% Xience EES (0.06 ± 0.01 mm; P = 0.00001) compared BMS (0.15 0.03 mm) Resolute ZES (0.12 0.04 mm). Luminal area largest (3.79 0.33 mm(2) ; 0.0003 vs. BMS), followed (3.46 0.45 0.083 BMS) (3.07 0.53 ). Percentage stenosis smallest (17.23 3.64%; 0.00001), while (30.25 7.48%) (30.79 7.15%) did not differ. Endothelial monolayer regrowth significantly lower (65 13%) versus (79 11%; 0.004). There no difference (74 10%) BMS. further associated a number of inflammatory cells surrounding the (7 2 per strut) comparison to (15 6; 0.0001) (17 9; 0.0005).In this model, suppressed thickening better, normal endothelial as BMS, less strut-induced inflammation.